CorMedix Inc (NASDAQ: CRMD)’s stock price has decreased by -6.00 compared to its previous closing price of 12.16. However, the company has seen a -7.07% decrease in its stock price over the last five trading sessions. zacks.com reported 2025-01-08 that CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.
Is It Worth Investing in CorMedix Inc (NASDAQ: CRMD) Right Now?
The stock has a 36-month beta value of 1.61. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRMD is 59.25M, and at present, short sellers hold a 11.95% of that float. On January 29, 2025, the average trading volume of CRMD was 1.24M shares.
CRMD’s Market Performance
The stock of CorMedix Inc (CRMD) has seen a -7.07% decrease in the past week, with a 34.47% rise in the past month, and a -12.35% fall in the past quarter. The volatility ratio for the week is 4.60%, and the volatility levels for the past 30 days are at 6.14% for CRMD. The simple moving average for the past 20 days is 5.10% for CRMD’s stock, with a 56.13% simple moving average for the past 200 days.
Analysts’ Opinion of CRMD
Many brokerage firms have already submitted their reports for CRMD stocks, with D. Boral Capital repeating the rating for CRMD by listing it as a “Buy.” The predicted price for CRMD in the upcoming period, according to D. Boral Capital is $15 based on the research report published on January 13, 2025 of the current year 2025.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see CRMD reach a price target of $13. The rating they have provided for CRMD stocks is “Buy” according to the report published on August 26th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to CRMD, setting the target price at $6 in the report published on August 10th of the previous year.
CRMD Trading at 14.04% from the 50-Day Moving Average
After a stumble in the market that brought CRMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.47% of loss for the given period.
Volatility was left at 6.14%, however, over the last 30 days, the volatility rate increased by 4.60%, as shares surge +41.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.33% upper at present.
During the last 5 trading sessions, CRMD fell by -5.57%, which changed the moving average for the period of 200-days by +81.77% in comparison to the 20-day moving average, which settled at $10.88. In addition, CorMedix Inc saw 41.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRMD starting from Mistry Erin, who purchase 1,500 shares at the price of $9.99 back on Oct 31 ’24. After this action, Mistry Erin now owns 52,011 shares of CorMedix Inc, valued at $14,985 using the latest closing price.
Hurlburt Elizabeth, the EVP of CorMedix Inc, sale 140,027 shares at $11.18 during a trade that took place back on Nov 14 ’24, which means that Hurlburt Elizabeth is holding 45,397 shares at $1,565,670 based on the most recent closing price.
Stock Fundamentals for CRMD
Current profitability levels for the company are sitting at:
- -4.06 for the present operating margin
- 0.84 for the gross margin
The net margin for CorMedix Inc stands at -3.67. The total capital return value is set at -0.86. Equity return is now at value -65.04, with -54.61 for asset returns.
Based on CorMedix Inc (CRMD), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -100.19. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1546.43.
Currently, EBITDA for the company is -48.89 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 52.55. The receivables turnover for the company is 0.72for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.96.
Conclusion
To sum up, CorMedix Inc (CRMD) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
